Cargando…

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

BACKGROUND: Species selectivity of DMXAA (5,6-dimethylxanthenone-4-acetic acid, Vadimezan) for murine cells over human cells could explain in part the recent disappointing phase III trials clinical results when preclinical studies were so promising. To identify analogues with greater human clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tijono, S M, Guo, K, Henare, K, Palmer, B D, Wang, L-C S, Albelda, S M, Ching, L-M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619269/ https://www.ncbi.nlm.nih.gov/pubmed/23481185 http://dx.doi.org/10.1038/bjc.2013.101

Ejemplares similares

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
por: Ching, L-M, et al.
Publicado: (2002)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
por: Jameson, M B, et al.
Publicado: (2003)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
por: Laws, A. L., et al.
Publicado: (1995)

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
por: Ching, L. M., et al.
Publicado: (1992)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
por: Brunstein, F, et al.
Publicado: (2006)

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
por: Ching, L. M., et al.
Publicado: (1995)

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
por: Ching, L. M., et al.
Publicado: (1998)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma
por: Sersa, G, et al.
Publicado: (2008)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
por: Cao, Z, et al.
Publicado: (1999)

Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology
por: Yin, Ting, et al.
Publicado: (2017)

Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach
por: Pan, Shu-Ting, et al.
Publicado: (2015)

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
por: Philpott, M., et al.
Publicado: (1997)

A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts
por: Gosslau, A, et al.
Publicado: (2005)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030
por: Lin, L, et al.
Publicado: (2011)

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
por: Moilanen, E., et al.
Publicado: (1998)

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
por: Yeow, W-S, et al.
Publicado: (2006)

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment
por: Byrne, A T, et al.
Publicado: (2009)

Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer
por: Araki, K, et al.
Publicado: (2010)

Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate
por: Khanim, F, et al.
Publicado: (2014)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas
por: Separovic, D, et al.
Publicado: (2009)

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
por: Weickhardt, A J, et al.
Publicado: (2015)

Identification of novel vascular targets in lung cancer
por: Zhuang, X, et al.
Publicado: (2015)

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
por: Santoro, A, et al.
Publicado: (2010)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
por: Coutelle, O, et al.
Publicado: (2015)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Expression of V(1A) and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition
por: MacKinnon, A C, et al.
Publicado: (2005)

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
por: Di Matteo, P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0218jflmg29i7rslvr3tich9cr